Apostolopoulou Sotiria C, Vagenakis George, Rammos Spyridon
Department of Pediatric Cardiology,Onassis Cardiac Surgery Center,Athens,Greece.
Cardiol Young. 2017 Nov;27(9):1861-1864. doi: 10.1017/S1047951117001548. Epub 2017 Aug 8.
We present the use of pulmonary vasodilators in three adult patients with unrepaired tetralogy of Fallot, pulmonary atresia, aortopulmonary collaterals, and segmental pulmonary arterial hypertension. Patients improved by 1-2 NYHA classes with modest exercise-tolerance increase, and remained stable without side effects during 2.5, 10, and 14 years. Literature review revealed five studies with pulmonary vasodilators in heterogeneous, mostly repaired patient populations.
我们展示了肺血管扩张剂在三名患有未经修复的法洛四联症、肺动脉闭锁、主肺动脉侧支和节段性肺动脉高压的成年患者中的应用。患者的纽约心脏协会(NYHA)心功能分级改善了1 - 2级,运动耐量有适度增加,并且在2.5年、10年和14年期间保持稳定,没有出现副作用。文献综述显示,有五项关于肺血管扩张剂在异质性患者群体(大多数为已修复患者)中的研究。